[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595776":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":29,"responsibleParty":48,"collaborators":10,"id":51,"slug":10,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":10,"maxAge":58,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Beijing Tsinghua Chang Gung Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Liver Resection Group",null,"This group included patients with type IVa BD who underwent liver resection, extrahepatic bile duct resection and Roux-en-Y hepaticojejunostomy",{"label":13,"type":10,"description":14,"interventionNames":10},"Hepaticojejunostomy Group","This group included patients with type IVa BD who underwent extrahepatic bile duct resection and Roux-en-Y hepaticojejunostomy",[16],{"name":17,"affiliation":18,"role":19},"Shuo Jin, PhD","Beijing Tsinghua Changgeng Hospital","PRINCIPAL_INVESTIGATOR",[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Changzhen Yang, MD","CONTACT","+86 18810915262","ycz23@mail.tsinghua.edu.cn",{"name":17,"role":23,"phone":27,"phoneExt":10,"email":28},"+86 18611172714","jsa01263@btch.edu.cn",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Beijing Tsinghua Changgung Hospital","RECRUITING","Beijing","Beijing Municipality","102218","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":46,"role":23,"phone":24,"phoneExt":10,"email":47},"Shuo Jin, M.D.","809262038@qq.com",{"type":19,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Shuo Jin","Associate Chief Physician","100595776",false,"NCT07036848","Efficacy and Safety of Surgical Treatment for Type IVa CBD","The Efficacy and Safety of Surgical Treatment in Type IVa Congenital Biliary Dilation: A Multi-center Cohort Study","Inclusion Criteria:\n\n1. Patients who have been diagnosed with Todani type IVa BD.\n2. Patients aged between 0 and 80 years old, regardless of gender.\n3. First-time receipt of surgery.\n\nExclusion Criteria:\n\n1. With abnormal intrapancreatic bile duct\n2. Inappropriate Roux-loop length (outside the range of 40-60 cm for adults and 15-30 cm for children)\n3. With non-relevant surgical interventions\n4. Pathologically confirmed carcinogenesis\n5. Unresolved choledocholithiasis, bile duct stenosis, and Intrahepatic bile duct stones during the procedure.\n6. Unavailable follow-up information.","ALL","80 Years",{"count":60,"type":61},1500,"ESTIMATED","OBSERVATIONAL","This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for IVa biliary dilatation (BD). Based on this cohort, the study seeks to compare the perioperative risks, long-term outcomes, and quality of life of type IVa BD following surgical treatment, to establish standardized surgical treatment strategies for type IVa BD.",[65],"Choledochal Cyst",[67],"Biliary Dilatation, Cohort Study, Surgical Treatment","2025-07-14",{"date":70,"type":71},"2025-07-17","ACTUAL",{"date":68,"type":71},{"date":74,"type":61},"2035-07-01",{"name":5,"class":6},1]